For deal sourcers, staying current on private company activity is critical to spotting active buyers, tracking market trends, and uncovering emerging investment opportunities ahead of competitors.
In January alone, we added more than 1,900 new private company transactions, bringing the total to over 17,300 searchable deals across sectors, industries, and transaction types in Dakota Marketplace.
Inside Dakota Marketplace, you’ll find the transactions tab that provides structured, filterable data on deal types, values, and dates, while our editorial team curates daily updates through the dakota transactions newsletter, helping you cut through the noise and focus on what matters most.
To ensure the most comprehensive coverage of private market activity, Dakota monitors over 10,000 websites including company websites, newswires, and numerous third-party news providers to capture and verify transaction data as it happens.
Below are the top 10 health care transactions.
- Transaction Date: 1/15/2026
- Industry: Health Care Equipment & Supplies
- Type: Acquisition / Merger
- Transaction Value: $14.5B
Boston Scientific agreed to acquire Penumbra in a cash-and-stock transaction valuing the company at approximately $14.5 billion, or $374 per share, expanding Boston Scientific’s presence in fast-growing vascular and neurovascular segments. The acquisition adds Penumbra’s differentiated thrombectomy and embolization technologies and is expected to be modestly dilutive to earnings in year one, with increasing accretion over time as revenue growth and scale benefits are realized.
- Transaction Date: 1/20/2026
- Industry: Biotechnology
- Type: Acquisition / Merger
- Transaction Value: $2.2B
GSK agreed to acquire RAPT Therapeutics for $58.00 per share in an all-cash transaction valuing the company at approximately $2.2 billion, adding ozureprubart, a phase IIb long-acting anti-IgE monoclonal antibody, to its immunology pipeline. The deal strengthens GSK’s position in food allergy treatment by targeting a validated pathway with the potential for less frequent dosing and improved patient outcomes, and is expected to close in the first quarter of 2026.
- Transaction Date: 1/20/2026
- Industry: Pharmaceuticals
- Type: Acquisition / Merger
- Transaction Value: $2.13B
GSK and Shionogi agreed to replace Pfizer’s 11.7% economic interest in ViiV Healthcare with a new $2.125 billion investment from Shionogi, increasing Shionogi’s stake to 21.7% while GSK retains its 78.3% majority ownership. The transaction simplifies ViiV’s shareholder structure, provides Pfizer $1.875 billion in cash and a $250 million special dividend to GSK, and is expected to close in the first quarter of 2026.
- Transaction Date: 1/14/2026
- Industry: Health Care Providers & Services
- Type: Buyout / Private Equity
- Transaction Value: $1.58B
Dentalcorp completed its acquisition by investment funds affiliated with GTCR in an all-cash transaction valuing the company at approximately C$2.2 billion in equity value and C$3.3 billion in enterprise value, with shareholders receiving C$11.00 per share. Following the deal, Dentalcorp will be taken private, delisted from the TSX, and continue under GTCR ownership alongside rollover investments from management and partner dentists.
- Transaction Date: 1/26/2026
- Industry: Biotechnology
- Type: Acquisition/Merger
- Transaction Value: $8.2M
Mirum Pharmaceuticals completed its acquisition of Bluejay Therapeutics in a cash-and-stock transaction, adding worldwide rights to brelovitug, a late-stage monoclonal antibody for chronic hepatitis delta virus with Breakthrough Therapy and PRIME designations. The deal strengthens Mirum’s leadership in rare liver diseases and is supported by concurrent private placement financings to fund Phase 3 development, with topline AZURE trial data expected in the second half of 2026.
- Transaction Date: 1/23/26
- Industry: Pharmaceuticals
- Type: Acquisition / Merger
- Transaction Value: $700M
BioCryst completed its acquisition of Astria Therapeutics in a cash-and-stock transaction valued at approximately $700 million in enterprise value, strengthening its leadership in hereditary angioedema with the addition of navenibart, a late-stage, long-acting injectable therapy in Phase 3 development. The deal expands BioCryst’s HAE portfolio alongside ORLADEYO® and is expected to support long-term growth by leveraging the company’s existing commercial infrastructure with minimal incremental investment.
- Transaction Date: 1/22/2026
- Industry: Health Care Equipment & Supplies
- Type: Acquisition / Merger
- Transaction Value: $685M
Perimeter Solutions completed its acquisition of Medical Manufacturing Technologies from Arcline Investment Management for approximately $685 million in cash, adding a leading provider of engineered machinery and aftermarket solutions for minimally invasive medical device manufacturing. The transaction expands Perimeter’s Specialty Products segment with a high-margin, proprietary business, roughly half of whose revenue is generated from recurring aftermarket services and consumables.
- Transaction Date: 1/18/2026
- Industry: Biotechnology
- Type: Asset Purchase
- Transaction Value: $630M
AstraZeneca agreed to acquire AbelZeta’s remaining 50% China rights to the GPC3-targeted CAR-T therapy C-CAR031, gaining full global development, manufacturing, and commercialization control of the program. AbelZeta is eligible to receive up to $630 million in upfront and milestone payments for the China rights, in addition to potential milestones and royalties tied to development outside China.
- Transaction Date: 1/12/2026
- Industry: Food Products
- Type: Acquisition / Merger
- Transaction Value: $510M
Charles River Laboratories announced plans to acquire K.F. (Cambodia) Ltd. for approximately $510 million to vertically integrate and secure its non-human primate supply chain for Discovery and Safety Assessment, a deal expected to be meaningfully accretive to non-GAAP EPS in 2026 and 2027. The company also exercised its option to acquire the remaining 79% of PathoQuest SAS for roughly $60 million, expanding its biologics testing capabilities with rapid, in vitro, next-generation sequencing solutions aligned with efforts to reduce animal use.
- Transaction Date: 1/6/2026
- Industry: Health Care Equipment & Supplies
- Type: Acquisition / Merger
- Transaction Value: $470M
A. O. Smith completed its acquisition of Leonard Valve Company from Bessemer Investors, adding a leading provider of water temperature and flow control solutions used in critical institutional and commercial applications. The transaction expands A. O. Smith’s portfolio in digital mixing, thermostatic controls, and hydronic system management, including the Heat-Timer platform, strengthening its position in safety- and efficiency-driven building solutions.
At Dakota, we understand how important it is to stay current on deal activity as it happens. That’s why our editorial team continuously monitors the news for real-time updates on platform investments, add-ons, divestitures, and more to deliver daily highlights straight to your inbox through our transactions newsletter.
Inside Dakota Marketplace, the transactions tab provides structured, filterable data with deal dates, types, sectors, and financials, allowing you to build a customized feed that aligns with your focus areas.
Whether you're evaluating a new investment opportunity or tracking trends within a target sector, Dakota Marketplace helps you cut through the noise and focus on what matters most.
For more information on these transactions and a deeper dive into their industries and sub-industries, book a demo of Dakota Marketplace.
